BCG
Binah Capital Group, Inc.
1.53
1 x 1.59
1 x 1.62
bid
ask
-
0.01
0.65%
1 @ 04:00 PM
1.53 +0.00 (0.00%)
Ytd-46.87%
1y-23.50%
1.52
day range
1.56
1.36
52 week range
3.44
Open1.53Prev Close1.54Low1.52High1.56Mkt Cap25.72M
Vol17.38KAvg Vol89.29KEPS0.09P/E17.00Forward P/EN/A
Beta0.46Short Ratio3.42Inst. Own0.43%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg1.74200-d Avg2.021yr Est0.00

BCG News

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
gurufocus.com
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-vi

81% of Enterprises Report AI Initiatives Delayed, Scaled Back, or Abandoned Due to Data Permission and Governance Gaps, Finds Transcend Research
businesswire.com
81% of Enterprises Report AI Initiatives Delayed, Scaled Back, or Abandoned Due to Data Permission a

SAN FRANCISCO--(BUSINESS WIRE)--Transcend, the autonomous "can I use this data?" platform that power

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
gurufocus.com
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C I

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
gurufocus.com
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients wi

AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
businesswire.com
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients wi

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus

TVS Motor Company Ranked #1 Globally For Shareholder Value Creation In 'Durable Consumer Goods' By WirtschaftsWoche And Boston Consulting Group
gurufocus.com
TVS Motor Company Ranked #1 Globally For Shareholder Value Creation In 'Durable Consumer Goods' By W

TVS Motor Company, part of TVS VENU, has been ranked #1 globally in the ‘Durable Consumer Goods' c

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
gurufocus.com
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive N

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
gurufocus.com
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BC

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherap

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
gurufocus.com
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherap

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
gurufocus.com
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou

Binah Capital Group Reports Results for First Quarter of 2026
globenewswire.com
Binah Capital Group Reports Results for First Quarter of 2026

- Assets Under Management (“AuM”) Increased 12.9% Year-over-Year to $29.0 Billion - - Increased Net

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
globenewswire.com
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intraves

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the IT

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
globenewswire.com
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the

TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-mo

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
prnewswire.com
Groundbreaking global survey captures the significant patient burden experienced with current standa

More than 90% of patients surveyed who underwent bladder removal or received BCG report negative imp

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
globenewswire.com
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Stron

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in

Binah Capital Group (NASDAQ:BCG)  Shares Down 9%   – Here’s What Happened
defenseworld.net
Binah Capital Group (NASDAQ:BCG) Shares Down 9% – Here’s What Happened

Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report)'s stock price fell 9% during mid-day tradi

Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result

Binah Capital Group (BCG) Stock Surges 59% After Hours — Here's Why
benzinga.com
Binah Capital Group (BCG) Stock Surges 59% After Hours — Here's Why

Binah Capital surged 59.20% in after-hours trading on strong fourth-quarter and full-year results, p

benzinga.com
Binah Capital Group Q4 EPS $0.01 Up From $(0.07) YoY, Sales $50.512M Up From $44.608M YoY

Binah Capital Group (NASDAQ:BCG) reported quarterly earnings of $0.01 per share. This is a 114.29 pe

Binah Capital Group Reports Results for Fourth Quarter and Full Year 2025
globenewswire.com
Binah Capital Group Reports Results for Fourth Quarter and Full Year 2025

– Grew Total Revenue 11% Year-over-Year to $187.1 Million – – Assets Under Management (“AuM”) Increa

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
globenewswire.com
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC

Binah Capital Group (NASDAQ:BCG) versus Barings Participation Investors (NYSE:MPV) Financial Comparison
defenseworld.net
Binah Capital Group (NASDAQ:BCG) versus Barings Participation Investors (NYSE:MPV) Financial Compari

Barings Participation Investors (NYSE: MPV - Get Free Report) and Binah Capital Group (NASDAQ: BCG -

benzinga.com
Market-Moving News for November 14th

BNO, USO: ~1.5% | Oil is trading higher amid reports of Iran seizing an oil tanker in the Strait of

Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Why Binah Capital (BCG) Stock Jumped 75% In After-Hours Trading
benzinga.com
Why Binah Capital (BCG) Stock Jumped 75% In After-Hours Trading

Binah Capital jumped 74.76% in after-hours trading following stronger-than-expected Q3 results.

benzinga.com
Binah Capital Group Q3 EPS $0.08 Up From $(0.09) YoY, Sales $46.198M Up From $42.197M YoY

Binah Capital Group (NASDAQ:BCG) reported quarterly earnings of $0.08 per share. This is a 188.89 pe

benzinga.com
CORRECTION: Binah Capital Group Q1 EPS $0.06 Up From $(0.14) YoY, Sales $48.94M Up From $41.45M YoY

Binah Capital Group (NASDAQ:BCG) reported quarterly earnings of $0.06 per share. This is a 142.86 pe

benzinga.com
12 Financials Stocks Moving In Monday's Intraday Session

benzinga.com
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day S

benzinga.com
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the compan

benzinga.com
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's M

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourt

benzinga.com
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the comp

benzinga.com
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarter